Kyowa Kirin, Inc.
kyowakirin.comTotal trials
36
Active
2
Phase 3
9
Total enrollment
5,123
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| KK2223 | — | — | — | — | — | 1 |
Next readouts
- 2029-03
Top conditions
- Parkinson's Disease8
- X-Linked Hypophosphatemia3
- X-linked Hypophosphatemia3
- Solid Tumor2
- Cancer2
- Carcinoma2
- T-cell NHL (PTCL or CTCL)1
- Cutaneous T-Cell Lymphoma, Relapsed1
Frequently asked questions about Kyowa Kirin, Inc.
- How many clinical trials does Kyowa Kirin, Inc. have on ClinicalTrials.gov?
- Kyowa Kirin, Inc. is listed as the lead sponsor on 36 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Kyowa Kirin, Inc.'s trials are in Phase 3?
- 9 of Kyowa Kirin, Inc.'s trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Kyowa Kirin, Inc. focus on?
- Kyowa Kirin, Inc.'s most-studied conditions on ClinicalTrials.gov are Parkinson's Disease, X-Linked Hypophosphatemia, X-linked Hypophosphatemia, Solid Tumor, Cancer.
- When are Kyowa Kirin, Inc.'s next clinical trial readouts?
- Kyowa Kirin, Inc. has 1 upcoming primary-completion readout tracked here; the soonest is “A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma”, expected around 2029-03.